Company intelligence / Profile preview

Altucell

Deer Park, New York, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Altucell's lead program utilizes microencapsulated human islet cells to deliver long-term insulin independence in type 1 diabetes; the technology has shown long-term safety in humans, and a Phase 1 clinical trial is IND-approved in Italy but, as of the most recent data, not yet listed as recruiting in public registries. Product portfolio remains in early-stage development, with ongoing or recently completed preclinical and early clinical proof-of-concept studies showing no toxicity or tissue necrosis in implanted subjects over up to 5 years[1][3].

Therapeutic areas: ImmunologyNeurologyEndocrinology
Modalities: Cell therapyBiologic
Industry: Biotech

Drug pipeline

3 assets

ALTUSTEM

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Generex Biotechnology

Beyond the preview

Go deeper on Altucell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altucell.

Explore the full profile